Latest Europe News

SciDev Ltd reports a seasonal revenue dip in Q2 FY25 due to US Oil & Gas sector uncertainty but marks a strategic milestone by securing its first PFAS treatment contracts in Europe.

Bio-Gene Technology Limited has advanced its bio-insecticide pipeline with two U.S. Department of Defense grants totaling A$3 million, alongside key regulatory and production milestones for Flavocide® and Qcide®.

Narryer Metals has reported a significant new critical minerals discovery at its Rocky Gully project, revealing high-grade scandium and rare earth element mineralisation alongside successful capital raising to fund further exploration.

Redivium's Q2 FY25 report reveals strategic progress in lithium-ion battery recycling across Europe, including new partnerships and feasibility studies, while navigating tight cash reserves and a critical entitlement offer.

Opyl Limited's Q2 FY25 update reveals robust progress through key partnerships, a new AI Biotech Fund launch, and strengthened financial footing, positioning the company for expanded influence in clinical trial optimisation.

ADX Energy reported steady production with 218 BOEPD and A$2.3 million revenue in Q4 2024, while progressing exploration in Austria and securing a new gas permit offshore Italy.

Altech Batteries Limited has made significant strides in funding and technology for its CERENERGY® battery project, including a $4 million capital raise and a breakthrough 55% increase in lithium-ion battery anode energy density.

DroneShield has secured three contracts worth $11.8 million from an Asia Pacific military customer, signaling growing adoption of its counter-drone technology in the region.

Lykos Metals Limited narrows its Sockovac project tenement while securing an extended exploration permit for Jezero, positioning itself for focused growth in Bosnia and Herzegovina.

Close the Loop Limited has ended acquisition discussions with Adamantem Capital but remains confident in its standalone growth strategy, projecting steady revenue and an EBITDA range of $11m-$13m for the first half of 2025.

Neurizon Therapeutics reports encouraging 8-month interim results for its ALS drug NUZ-001, secures Orphan Medicinal Product Designation in Europe, and raises $885,000 through a share placement, maintaining a robust $14 million cash position.

Infinity Lithium reports steady progress on its San José Lithium Project with updated mining licence requirements and a strategic pivot to new European funding opportunities.